As all of the melanoma lines tested responded to treatment in a similar manner in the in vitro assays, we chose to perform the mouse xenograft experiments with the WM1366 cell line (CDK2 low/NRAS mutated) to assess if the compound would still be effective if CDK2 levels were low. Here, CDK2 is linked to melanoma.